A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights.
Mohammad M Al-SaneaAhmad J ObaidullahMohamed E ShakerGarri ChilingaryanA F M Motiur RahmanNawaf A AlsaifHamad M Al KahtaniSultan A AlsubaieMohamed A AbdelgawadPublished in: Molecules (Basel, Switzerland) (2021)
These findings displayed a substantial basis of synthesizing further derivatives based on the 3-hydrazonoindolin-2-one scaffold for favorable targeting of breast cancer.